From: Recent advances in nanotheranostics for triple negative breast cancer treatment
Class of agents | Agent | Phase | Participants | Combinatorial agent | Completion | Identifier |
---|---|---|---|---|---|---|
AR antagonist | Enzalutamide | 2 | Stage I-III AR positive TNBC | - | April 2019 | NCT02750358 |
Anti-PD1 | Pembrolizumab | 1/2 | Recurrent TNBC, mTNBC | PLX3397 (TkI of KIR, CSFIR) | May 2019 | NCT02452424 |
Anti-PD1 | Pembrolizumab | 2 | mTNBC | Carboplatin + gemcitabine | June 2019 | NCT02755272 |
Hsp90 inhibitors | Onalespib | 1 | Metastatic solid tumor, Recurrent TNBC | Olaparib | October 2019 | NCT02898207 |
AR antagonist | Enzalutamide | 1/2 | AR positive mTNBC | Taselisib (PI3K inhibitor) | December 2019 | NCT02457910 |
Anti-PD1 | Pembrolizumab | 3 | Recurrent TNBC and mTNBC | Nab-paclitaxel /Paclitaxel/gemcitabine/ carboplatin | December 2019 | NCT02819518 |
PARPi | Olaparib | 3 | TNBC, Germline BRCA1/2 mutation | - | March 2020 | NCT02032823 |
PARPi | Olaparib | 1b | Recurrent TnBc | AZD2014 (mTORC1/2 inhibitor) | November 2020 | NCT02208375 |
AR antagonist | Enzalutamide | 2 | AR positive mTNBC | Paclitaxel | December 2020 | NCT02689427 |
Anti-PD1 | Pembrolizumab | 2 | Advanced TNBC or mTNBC | - | January 2021 | NCT02644369 |
Anti-PD-L1 | MPDL3280A | 2 | TNBC | Nab-paclitaxel | February 2021 | NCT02530489 |
Anti-PD1 | Pembrolizumab | 1/2 | mTNBC | Paclitaxel | May 2021 | NCT02734290 |